In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumors (NETs), a rare but increasingly prevalent ...
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at Washington ...
SEATTLE, WA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of preclinical data from two ...
Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers through ...
A schematic of the study. The simple targeted alpha-particle therapy (TAT) compound was made by joining the radionuclide astatine-211 to an azide. The TAT compound was injected into a mice that had ...
Researchers have developed a new type of tumor-targeted alpha-particle therapy that has the potential to generically treat several kinds of cancer, with fewer negative side effects than currently ...
MTX and VBL treatment for patients with desmoid tumors resistant to meloxicam treatment: Relationship between efficacy and CTNNB1 mutation status. This is an ASCO Meeting Abstract from the 2014 ASCO ...
[212 Pb]VMT-α-NET shows promise in effectively treating neuroendocrine tumors Administration of fractionated doses of [212 Pb]VMT-α-NET shows 100% survival in a robust model of metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results